Transdermal Or Percutaneous Patents (Class 424/449)
-
Patent number: 8221784Abstract: A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix comprising an effective amount of at least a progestin hormone, delivery of which is enhanced by one or more skin permeation enhancing agents present in pre-determined amounts. The THDS is capable of providing effective daily doses of progestin and estrogen hormones from a small surface area in contact with the skin, e.g., less than 20 square centimeters. Methods of fertility control and various types of hormone replacement therapy utilizing the THDS are also disclosed.Type: GrantFiled: August 19, 2009Date of Patent: July 17, 2012Assignee: Agile Therapeutics, Inc.Inventor: Te-Yen Chien
-
Patent number: 8221785Abstract: A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix comprising an effective amount of at least a progestin hormone, delivery of which is enhanced by one or more skin permeation enhancing agents present in pre-determined amounts. The THDS is capable of providing effective daily doses of progestin and estrogen hormones from a small surface area in contact with the skin, e.g., less than 20 square centimeters. Methods of fertility control and various types of hormone replacement therapy utilizing the THDS are also disclosed.Type: GrantFiled: September 10, 2009Date of Patent: July 17, 2012Assignee: Agile Therapeutics, Inc.Inventor: Te-Yen Chien
-
Patent number: 8216606Abstract: A dermal composition for administration of a drug comprising a blend of two or more acrylic-based polymers having differing functionalities so as to modulate the drug solubility in the polymer matrix and the delivery rate of the drug, and methods therefor.Type: GrantFiled: October 24, 2005Date of Patent: July 10, 2012Assignee: Noven Pharmaceuticals, Inc.Inventors: David Houze, Juan Mantelle, David Kanios
-
Publication number: 20120171278Abstract: A transdermal patch comprising a backing 2 and an adhesive layer 3 laminated on the backing 2, wherein the adhesive layer 3 comprises a rosin-based resin and petroleum resin as a tackifier, the total compounding amount of the rosin-based resin and the petroleum resin is in a range of 15% by mass to 50% by mass, and compounding amount of the petroleum resin is 1/3 times by mass to 4 times by mass as that of the rosin-based resin.Type: ApplicationFiled: March 13, 2012Publication date: July 5, 2012Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Yasunori TAKADA, Koji TANAKA, Yasuhiro IKEURA
-
Publication number: 20120171277Abstract: A transdermal drug delivery patch has an excipient matrix containing an agonist for administration across the skin of a user, with the matrix further containing a plurality of spaced apart hollow cilia filled with an antagonist, whereby if an abuser attempts to physically remove the agonist the cilia will break releasing the antagonist, or if the abuser attempts to use a solvent to remove the agonist the cilia will dissolve releasing the antagonist, thereby blocking the effect the abuser is attempting to attain by concentrating the agonist for oral ingestion or by hypodermic needle injection. The plurality of spaced apart hollow cilia further includes a release-enhancing agent in association with the antagonist for increasing the release rate of the antagonist.Type: ApplicationFiled: January 3, 2011Publication date: July 5, 2012Inventor: Robert B. Royds
-
Patent number: 8211462Abstract: This patent application relates to a transdermal therapeutic system (TTS) that comprises a Rotigotine-containing cement layer, characterized in that the cement layer contains a hot-meltable adhesive in which Rotigotine as the active substance is dispersed and partly or completely dissolved. The patent application further relates to the use of Rotigotine in the production of the cement layer of a TTS by a hot-melt method.Type: GrantFiled: July 29, 2003Date of Patent: July 3, 2012Assignee: UCB Pharma GmbHInventors: Armin Breitenbach, Hans-Michael Wolff
-
Patent number: 8206738Abstract: A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.Type: GrantFiled: September 12, 2003Date of Patent: June 26, 2012Assignees: Corium International, Inc., A.V. Topchiev Institute of Petrochemical SynthesisInventors: Parminder Singh, Adrian Faasse, Gary W. Cleary, Sri Mudumba, Mikhail M. Feldstein, Danir R. Bairamov
-
Publication number: 20120156279Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of peptides and peptide-related compounds, which are capable of crossing biological barriers with higher penetration efficiency comparing to their parent drugs. The HPPs are capable of being converted to parent drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs/HPCs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs/HPCs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: ApplicationFiled: November 8, 2011Publication date: June 21, 2012Inventors: Chongxi Yu, Lina Xu, Yuhua Chen, Binbing Yan, Shiqian Tu
-
Patent number: 8202533Abstract: The present invention describes a new method for progressive desensitization of a subject to groundnut. More specifically, the invention relates to the immunotherapeutic method for increasing groundnut tolerance in an allergic subject using epicutaneous administration. The present invention is also relative to the use of a skin patch device for progressive desensitization of a subject to groundnut.Type: GrantFiled: November 30, 2009Date of Patent: June 19, 2012Assignee: DBV TechnologiesInventors: Lucie Mondoulet, Christophe Dupont, Pierre-Henri Benhamou, Bertrand Dupont
-
Patent number: 8197843Abstract: An article having an adhesive surface for adhering to human skin that includes a first component constituting a continuous layer and at least a second component which is located in indentations in the adhesive surface of the first component without being in direct contact with the first component. The second component is separated from the first component by a cup shaped barrier layer having a rim which extends into a flange.Type: GrantFiled: September 20, 2002Date of Patent: June 12, 2012Assignee: Coloplast A/SInventors: Michael Pilgaard, Jan Marcussen
-
Patent number: 8197844Abstract: A transdermal medicament patch includes a biocompatible substrate having a therapeutic face on one side configured for disposition against the skin of a patient, a biocompatible adhesive on the therapeutic face, a planar medicament matrix covering a portion of the therapeutic face, and a release liner covering the portion of therapeutic that is not obscured by the medicament matrix. An aperture formed through the release sheet affords direct access by medicament to the entire surface of the medicament matrix opposite from the therapeutic face of the substrate. An active electrode positioned between the medicament matrix and the therapeutic face of the substrate includes an electrically conductive backing layer positioned against the therapeutic face of the substrate and a pH-control layer covering less than all of the side of the backing layer opposite from the therapeutic face of the substrate.Type: GrantFiled: June 8, 2007Date of Patent: June 12, 2012Assignee: Activatek, Inc.Inventor: Jamal S. Yanaki
-
Patent number: 8187625Abstract: Disclosed is a biocompatible, hemostatic, cross-linked gelatin composition comprising a biocompatible material comprising cross-linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the sponge in the presence of an aqueous solution.Type: GrantFiled: February 4, 2002Date of Patent: May 29, 2012Assignee: Boston Scientific Scimed, Inc.Inventor: Richard J. Greff
-
Patent number: 8187628Abstract: A dermal composition for administration of an amphetamine drug comprising a blend of two or more acrylic-based polymers having differing functionalities so as to modulate the drug solubility in the polymer matrix and the delivery rate of the drug, and methods therefor.Type: GrantFiled: October 24, 2005Date of Patent: May 29, 2012Assignee: Noven Pharmaceuticals, Inc.Inventors: David Houze, Juan Mantelle, David Kanios
-
Patent number: 8183427Abstract: A biodegradable microfiber absorbent comprises a substantially homogeneous mixture of at least one hydrophilic polymer and at least one biodegradable polymer. The absorbent can be prepared by an electro hydrodynamic spinning of a substantially homogeneous polymer mixture. Medical dressings for burns and wounds, cavity dressings, drug delivery patches, face masks, implants, drug carriers that comprises at least one microfiber electrospun from a polymer mixture are provided. The dressings can have variable water vapor penetration characteristics and variable biodegradation times.Type: GrantFiled: December 7, 2010Date of Patent: May 22, 2012Inventors: Bronislava G. Belenkaya, Valentina I. Sakharova, Vyacheslav N. Polevov, Claudia Polevov, legal representative
-
Patent number: 8182833Abstract: A method for reducing the symptoms of peripheral vascular disease and for improving peripheral circulation wherein a progestin is administered to a subject in need thereof.Type: GrantFiled: July 2, 2009Date of Patent: May 22, 2012Assignee: Dimera IncorporatedInventor: R. Kent Hermsmeyer
-
Patent number: 8172815Abstract: A device includes a plurality of skin penetrating devices for delivering or withdrawing a substance through the skin of a patient. The device has a support formed with a top and bottom end and a plurality of channels extending axially through the support. A plurality of the skin penetrating members is positioned in the channels with a tip extending from the bottom end of the support. A coupling member is attached to the support for coupling with a fluid supply and directing the fluid to the skin penetrating members. The skin penetrating members have a length of about 100 microns to about 2000 microns and are about 30 to 50 gauge.Type: GrantFiled: May 23, 2003Date of Patent: May 8, 2012Assignee: Becton, Dickinson and CompanyInventors: James Down, Noel G. Harvey, Frank E. Martin, Ronald J. Pettis, Alexander G. Lastovich
-
Patent number: 8173155Abstract: The present invention relates an adhesive patch comprising a backing layer and an adhesive layer that contains a drug, wherein the adhesive layer contains a mixed adhesive base containing a hydrocarbon rubber and a silicon-containing polymer. The adhesive patch of the invention shows extremely superior skin absorbability of a drug in a preparation, reduced skin irritation, and excellent aging stability of the drug in the preparation, and can achieve easiness of drug-taking methods and improvement in compliance.Type: GrantFiled: May 31, 2005Date of Patent: May 8, 2012Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Takashi Yasukochi, Tetsuro Tateishi, Naruhito Higo
-
Patent number: 8173156Abstract: An anti-inflammatory-containing plaster is provided. The anti-inflammatory-containing plaster may include, e.g., a styrene-isoprene-styrene block copolymer, a high molecular weight polyisobutylene, a low molecular weight polyisobutylene, a tackifier, a plasticizer, a dispersant, and an anti-inflammatory having a carboxyl group or a salt thereof. However, the anti-inflammatory-containing plaster does not contain L-menthol. The anti-inflammatory-containing plaster has medicament release rates of 20-64% by mass and 40-93% by mass at one hour and three hours, respectively.Type: GrantFiled: June 10, 2009Date of Patent: May 8, 2012Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yasuhiro Ikeura, Miyuki Shinmura
-
Patent number: 8163725Abstract: Improved topical gel compositions for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.Type: GrantFiled: September 22, 2011Date of Patent: April 24, 2012Assignee: Galderma R&D SNCInventors: Jean-Christophe Buge, Karine Nadau-Fourcade, Cyril Meunier
-
Patent number: 8158145Abstract: A transdermal patch comprising a backing 2 and an adhesive layer 3 laminated on the backing 2, wherein the adhesive layer 3 comprises a rosin-based resin and petroleum resin as a tackifier, the total compounding amount of the rosin-based resin and the petroleum resin is in a range of 15% by mass to 50% by mass, and compounding amount of the petroleum resin is ? times by mass to 4 times by mass as that of the rosin-based resin.Type: GrantFiled: February 19, 2003Date of Patent: April 17, 2012Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yasunori Takada, Koji Tanaka, Yasuhiro Ikeura
-
Patent number: 8158845Abstract: A wound dressing comprises in combination (i) a first wound contact layer which preferably has a positive effect on the healing of the wound, and (ii) a second layer of greater hydrophilicity than the first layer.Type: GrantFiled: June 27, 2005Date of Patent: April 17, 2012Assignee: Advanced Medical Solutions LimitedInventors: Yimin Qin, Denis Keith Gilding
-
Patent number: 8155738Abstract: Device structure 100 for iontophoresis provides electrode 101 and electrically conductive layer 102. Electrically conductive layer 102 contains active ingredient D and basic water swelling methacrylate copolymer P1 and/or acidic water swelling methacrylate copolymer P2. Electrode 101 and electrically conductive layer 102 are placed into a hollow of backing 103 and electrode terminal 104 is connected to electrode 101 through backing 103. Adhesive layer 105 is set around backing 103, and liner 106 to be removed when using the device, is placed so as to cover the hollow of backing 103.Type: GrantFiled: October 1, 2010Date of Patent: April 10, 2012Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Hirotoshi Adachi, Noriyuki Kuzumaki, Tetsuya Arimoto, Naruhito Higo
-
Patent number: 8153151Abstract: Compositions and methods for controlling transdermal drug delivery, particularly of amine-functional and basic drugs, comprising a blend of a first silicone-based polymer having a reduced silanol concentration and a second silicone-based polymer have a substantial or high silanol concentration. The blend of such silicone-based polymers, particularly pressure-sensitive silicone adhesives, provides sufficient drug solubility and reduced initial drug delivery onset to permit a prolonged delivery duration at a substantially zero-order rate of delivery.Type: GrantFiled: September 29, 2008Date of Patent: April 10, 2012Assignee: Noven Pharmaceuticals, Inc.Inventor: David Houze
-
Patent number: 8146741Abstract: A blister package comprises a blister and a cover sheet, and the blister has a groove formed in an outer edge section of the blister. The outer edge section of the blister includes an outer region and an inner region, the groove is formed on the inward side of the outer region, and the inner region is formed on the inward side of the groove. The peel strength between the outer region and the cover sheet is greater than the tear strength of the cover sheet, and the peel strength between the inner region and cover sheet is smaller than the tear strength of the cover sheet.Type: GrantFiled: November 16, 2009Date of Patent: April 3, 2012Assignee: Nitto Denko CorporationInventors: Kensuke Matsuoka, Yoshihiro Iwao, Katsuhiro Okada
-
Publication number: 20120064146Abstract: A wound care device for local treatment of pain in a wound, said device comprising an active pain relieving composition, the device being constructed in such a manner that the pain killing agent is released to the wound in such a way that substantially no effective systemic plasma concentration of the pain killing agent can be found and wherein a majority of said pain killing agent is in direct contact with the wound.Type: ApplicationFiled: September 12, 2011Publication date: March 15, 2012Inventors: Gitte Juel Friis, Truels Sterm Larsen
-
Patent number: 8133505Abstract: The present invention provides a system for transdermal delivery of dried or lyophilized pharmaceutical compositions and methods using thereof. The system comprises an apparatus for facilitating transdermal delivery of an agent that generates hydrophilic micro-channels, and a patch comprising a therapeutically active agent. The present invention is useful for transdermal delivery of hydrophilic agents, particularly of high molecular weight proteins.Type: GrantFiled: January 21, 2009Date of Patent: March 13, 2012Assignee: TransPharma Medical Ltd.Inventors: Meir Stern, Galit Levin
-
Patent number: 8128964Abstract: A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.Type: GrantFiled: August 30, 2001Date of Patent: March 6, 2012Assignee: Queen Mary & Westfield CollegeInventors: Arthur T. Tucker, Nigel Benjamin
-
Patent number: 8127926Abstract: A patch package structure which includes: a package including a first sheet material which is planar and a second sheet material which has been molded, a peripheral area of the first sheet material having been sealed to a peripheral area of the second sheet material to constitute the package, and a patch disposed in the package; in which the patch includes a backing, a pressure-sensitive adhesive layer formed on at least one side of the backing, and a release liner which protects the pressure-sensitive adhesive surface of the pressure-sensitive adhesive layer, the release liner having a weakening line for assisting a removal of the release liner; and in which the second sheet material has specific first protrudent part, second protrudent part, third protrudent part and elevated part in a central area thereof except the peripheral area thereof.Type: GrantFiled: December 22, 2009Date of Patent: March 6, 2012Assignee: Nitto Denko CorporationInventors: Katsuhiro Okada, Yoshihiro Iwao, Kensuke Matsuoka
-
Publication number: 20120052112Abstract: A transdermal preparation is provided that contains risperidone and/or a pharmaceutically acceptable salt thereof as a drug, and the amount of the drug is 1 to 20 parts by mass based on 100 parts by mass of the total mass of the preparation. The skin permeation rate of the preparation is 0.5 to 30 ?g/cm2/hour, and the drug diffusion coefficient of the preparation in the skin is 1.2×10?6 to 10.0×10?6 cm/hour.Type: ApplicationFiled: February 19, 2010Publication date: March 1, 2012Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Mitsuru Kuribayashi, Motohiro Suzuki, Hidenao Fukushima, Eisuke Shimizu
-
Publication number: 20120052113Abstract: The present invention relates to a transdermal preparation having a backing and an adhesive layer laminated on the backing, wherein the adhesive layer contains 4E indolone and a physiologically active compound.Type: ApplicationFiled: May 7, 2010Publication date: March 1, 2012Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Naoyuki Uchida, Yuka Takagi, Yasunori Takada
-
Patent number: 8124122Abstract: Provided herein is a female hormone-containing patch wherein an active ingredient is highly soluble in a pressure-sensitive adhesive layer and the active ingredient is not adsorbed to a backing, and the patch per se can follow the irregularities on the skin surface or body movements. The patch is an external patch containing, as a female hormone, a follicular hormone estradiol and/or its derivative or a progestational hormone norethisterone and/or its derivative. The external patch comprises an acrylic pressure-sensitive adhesive containing 0.01 to 1% by weight of an isocyanate-based crosslinking agent as an essential ingredient.Type: GrantFiled: August 7, 2003Date of Patent: February 28, 2012Assignee: Teikoku Seiyaku Co., Ltd.Inventors: Takaya Sugahara, Sadanobu Shirai, Masahiro Yamaji
-
Patent number: 8114442Abstract: A pharmaceutically delivery system and method of use therefor are described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.Type: GrantFiled: September 3, 2008Date of Patent: February 14, 2012Assignee: Queen Mary & Westfield CollegeInventors: Arthur T. Tucker, Nigel Benjamin
-
Patent number: 8114434Abstract: The invention provides an analgesic anti-inflammatory patch of a hydrophobic type for topical application containing, in a Pressure Sensitive Adhesive(PSA), diclofenac sodium, pyrrolidone or a derivative thereof, a polyhydric alcohol fatty acid ester, and an organic acid. The patch exerts the following effects: (1) diclofenac sodium is effectively and continuously released from a Pressure Sensitive Adhesive(PSA) and percutaneously absorbed, thereby attaining sustained, excellent pharmaceutical and pharmacological effects; (2) the patch per se has high tackiness and safety; and (3) diclofenac sodium remains stable in the Pressure Sensitive Adhesive(PSA).Type: GrantFiled: November 9, 2009Date of Patent: February 14, 2012Assignees: Tokuhon Corporation, SSP Co., Ltd., Dojin Iyaku Kako Co., Ltd.Inventors: Yasuhiko Sasaki, Yukihiro Matsumura, Masaru Yamazaki, Hiroshi Arai, Shogo Kawabata, Masaaki Saito, Hirohisa Okuyama, Makoto Suzuki
-
Publication number: 20120034293Abstract: The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient.Type: ApplicationFiled: October 12, 2011Publication date: February 9, 2012Applicant: AllTranz Inc.Inventors: Audra L. Stinchcomb, Buchi N. Nalluri
-
Patent number: 8105624Abstract: Topical patch preparations that contain an odorless physiological cooling agent, and methods for using the same are provided. The subject topical patch preparations are made up of an adhesive gel composition that is present on a support, where the adhesive gel composition includes the odorless physiological cooling agent, a water-soluble polymer gel, water and a water holding agent. In using the subject topical patch preparations, the topical patch preparations are applied to a skin surface of a subject and maintained at the site of application for a period of time sufficient for an effective amount of the an odorless physiological cooling agent to be administered to the subject. The subject invention finds use in a variety of applications.Type: GrantFiled: December 16, 2005Date of Patent: January 31, 2012Assignee: Teikoku Pharma USA, Inc.Inventor: Jutaro Shudo
-
Patent number: 8092827Abstract: A medical non-crosslinked pressure-sensitive adhesive composition which not only has relatively high resistance to water during perspiration or the like and shows a sufficient skin adhesive force, but also can contain a large amount of a liquid plasticizer and hence have reduced skin-irritating properties. These compositions comprise an adhesive polymer A having a weight-average molecular weight of 500,000-1,000,000, an adhesive polymer B having a weight-average molecular weight of 1,000,000-1,500,000, and a liquid plasticizer, wherein the adhesive polymer A is a polymer obtained by copolymerizing one or more alkyl (meth)acrylates with N-vinyl-2-pyrrolidone and the adhesive polymer B is either a polymer obtained by the polymerization of one or more alkyl (meth)acrylates or a polymer obtained by copolymerizing one or more alkyl (meth)acrylates with one or more comonomers other than N-vinyl-2-pyrrolidone.Type: GrantFiled: April 26, 2005Date of Patent: January 10, 2012Assignee: Nitto Denko CorporationInventors: Keigo Inosaka, Takateru Muraoka
-
Publication number: 20110313372Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.Type: ApplicationFiled: June 17, 2011Publication date: December 22, 2011Inventors: René EIFLER, Michael Horstmann, Regine Kaufmann, Patrick Mohr
-
Patent number: 8080261Abstract: Gel compositions that contain 1-dichloro-2,4-dinitrobenzene (DNCB) are provided. Embodiments of the subject gel compositions include DNCB, an organic solvent and a viscosity agent, wherein the organic solvent and viscosity agent are inert with respect to the DNCB. Also provided are methods for using the subject compositions and kits for use in practicing the subject methods.Type: GrantFiled: November 8, 2005Date of Patent: December 20, 2011Assignee: Teikoku Pharma USA, Inc.Inventor: Jutaro Shudo
-
Publication number: 20110305734Abstract: The present invention provides nanoparticle compositions including one or more nucleic acids. The present invention achieves delivery (particularly transdermal delivery) of such nucleic acids without the need for nucleic acid modification, or for use of chemical or mechanical abrasion or disruption of skin.Type: ApplicationFiled: May 30, 2008Publication date: December 15, 2011Applicant: ANTERIOS, INC.Inventors: Jonathan Edelson, Timothy Kotyla, Boke Zhang
-
Publication number: 20110305746Abstract: The present invention relates to a patch for treating constipation, which contains rhubarb ingredients selected from among crude drugs (medical herbs). More particularly, the present invention relates to a patch for treating constipation in which powder obtained by boiling, filtering, and free-drying rhubarb selected from among pure crude drugs is applied to the patch, and the patch is attached to the recesses (arched parts) below the wrists of both hands of a patient, to thereby increase the metabolism of internal organs of the patient and exhibit the effects of treating or preventing constipation. The patch of the present invention can be simply attached to the skin of the patient instead of directly administering agents for treating constipation to the patient.Type: ApplicationFiled: February 19, 2010Publication date: December 15, 2011Inventor: Tae Jin Kim
-
Patent number: 8075912Abstract: The invention relates to a transdermal therapeutic system (TTS), preferably in the form of a transdermal plaster, that contains an active substance and an agent which can destroy the active substance. The TTS further includes a means of bringing the active substance, e.g. buprenorphine, and the agent, e.g. potassium permanganate, into contact when the TTS is removed from the skin of the patient, thereby causing the active substance to be destroyed.Type: GrantFiled: May 22, 2007Date of Patent: December 13, 2011Assignee: LTS Lohmann Therapie-Systeme AGInventors: Hans-Rainer Hoffmann, Thomas Hille
-
Patent number: 8075911Abstract: A transparent transdermal delivery device for delivering nicotine which has an Opacity Index of less than 48.6%.Type: GrantFiled: August 20, 2007Date of Patent: December 13, 2011Assignee: Alza CorporationInventor: Robert M. Gale
-
Patent number: 8071125Abstract: This invention relates to a transdermal patch in the form of a layer complex, comprising a backing layer, a drug-reservoir layer comprising pharmacologically active ingredients and pharmaceutically acceptable adjuvants, and a release liner covering the drug-reservoir layer, characterized in that the drug-reservoir layer comprises isosorbide dinitrate and Bisoprolol at a ratio of 1:3 to 3:1 by weight, as the pharmacologically active ingredients. Animal tests show that said patch can reduce the elevation of T wave of cardiogram, the increase of the level of myocardial enzyme in blood serum, and the extension of the range of myocardial infarction caused by ligating the coronary artery in animals. Results show that said patch exhibits a considerable synergistic effect in the treatment of cardiovascular diseases and has good preventive and therapeutic effects on several adverse events on heart.Type: GrantFiled: December 9, 2005Date of Patent: December 6, 2011Assignee: Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd.Inventors: Shuming Wang, Li Wang, Xiaoling Fan, Huiyong Xue, Shuang Zhang, Enhong Zhang, Xuying Zhong, Yucheng Lu, Chun Li, Li Song
-
Patent number: 8071126Abstract: A percutaneous absorption type patch adapted to be applied to a skin surface of a patient. The percutaneous absorption type patch comprises: a stratum-corneum release member constituted from a sheet-like first supporting substrate and a pressure-sensitive adhesive layer laminated on the first supporting member; a medicinal-components administration member constituted from a sheet-like second supporting substrate, a medicinal-components retention layer laminated on the second supporting substrate, and a protect layer laminated on the medicinal-components retention layer; and a sheet-like handling member interposed between the stratum-corneum release member and the medicinal-components administration member. An edge portion of the handling member is coupled to or integrated with both the first supporting substrate and the protect layer.Type: GrantFiled: March 19, 2008Date of Patent: December 6, 2011Assignee: LINTEC CorporationInventors: Toru Sekiguchi, Kaname Nakahara, Toru Watanabe
-
Patent number: 8071075Abstract: The invention relates to a method for treatment or prophylaxis of a disease or condition in an animal comprising administering to a mucosal membrane of said animal in need of such treatment a therapeutically effective amount of a drug delivery system comprising at least one physiologically active agent or prodrug thereof and at least one penetration enhancer selected from safe ester sunscreens.Type: GrantFiled: October 5, 2007Date of Patent: December 6, 2011Assignee: Acrux DDS Pty Ltd.Inventors: Barry Leonard Reed, Timothy Matthias Morgan, Barrie Charles Finnin
-
Patent number: 8053427Abstract: Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.Type: GrantFiled: June 13, 2011Date of Patent: November 8, 2011Assignee: Galderma R&D SNCInventors: Jean-Christophe Buge, Karine Nadau-Fourcade, Cyril Meunier
-
Publication number: 20110268786Abstract: The invention relates to a transdermal, especially dopaminergic patch, comprising a release liner film, an active substance layer, and a carrier film, wherein the active substance layer is applied between the release liner film and the carrier film. The release liner film and/or the carrier film thereby comprise at least one separation edge brought about thermally, at least partially defining a peripheral edge of the patch. The invention further relates to a method for producing such a transdermal patch and to a tool for producing the patch according to the method according to the invention. Crystal growth in the active substance layer can be reliably prevented by the patch according to the invention.Type: ApplicationFiled: December 22, 2009Publication date: November 3, 2011Applicant: UCB PHARMA GMBHInventor: Ingolf Jasch
-
Patent number: 8048927Abstract: The present invention provides methods for treating and preventing benign breast disease by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with benign breast disease, this effect induces disease regression. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents formation of benign breast conditions that can lead to cancer.Type: GrantFiled: March 4, 2009Date of Patent: November 1, 2011Assignee: Besins Healthcare LuxembourgInventor: Elisabeth Le Nestour
-
Publication number: 20110256211Abstract: Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.Type: ApplicationFiled: October 7, 2009Publication date: October 20, 2011Inventors: Thomas M. Rossi, Marie Foegh, Agis Kydonieus
-
Patent number: 8039023Abstract: A composition is disclosed which provides relief from menstrual cramps and muscle cramps within three to seven minutes after ingestion. The composition is preferably a mixture in the form of an aqueous solution with components mixed within approximately fifty percent of the following amounts: 60 mg/liter of calcium gluconate, 75 mg/liter of potassium bicarbonate, 90 mg/liter of L glutamine, 5 mg/liter of calcium chloride, 150 mg/liter of potassium chloride; 60 mg/liter of calcium ascorbate; 100 mg/liter of magnesium glycinate, and 15 mg/liter of potassium citrate. The liquid solution is taken by a human in a dosage of one to four ounces, depending upon the body weight of the person, whether the person is experiencing menstrual cramps or muscle cramps, and the area affected when the person is seeking relief from muscle cramps.Type: GrantFiled: April 8, 2009Date of Patent: October 18, 2011Inventor: Robert Gaylon Ross, Sr.